From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Synairgen – Why I bought, continue to hold and an apology

By Peter Brailey | Tuesday 21 July 2020


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Synairgen (SYN) came onto my radar earlier this year. I bought. After yesterday’s monumental rise I’m quids in, and remain a holder. But I owe an apology – I dropped it from my final buy tip selection recorded for last weekend’s Mineprophets show. As discussed with Tom Winnifrith, I did not consider myself sufficiently expert to tip mining shares. Synairgen is a drug company, which is also not my area of expertise, however I liked the investment case but could not tip it – what do I know about bio-meds? Perhaps I should be bolder and more confident?

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

CTAI

Catenai – monster dilution

Time left: 18:58:58